Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1326190 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $2.98Day +2.05%Mkt cap $580M1Y −18.4%Off 52W high −53.7%Vol (1Y) 69.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,587 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest24.8% of sh out |
| Days to cover12.5d |
| 13F net flow (QoQ)+6.33% |
| Top-10 13F concentration70.4% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$41,000 |
| Earnings (TTM)-$91.1M |
| ROE−50.6% |
| Net margin−214861.0% |
| Debt / equity0.15× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−17.5% |
| 1Y−18.4% |
| 3Y−10.0% |
| 5Y−67.1% |
| Since incept. (ann.)−0.3% |
Total return through 2026-07-30 · series begins 2020-04-01. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)69.3% |
| Ann. volatility (3Y)92.5% |
| Sharpe (1Y)−0.01 |
| Sharpe (3Y)0.44 |
| Max drawdown (1Y)−58.1% |
| Max drawdown (3Y)−81.2% |
| Beta (3Y vs SPY)3.60 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 12.8M | $39M | 9.84% | +31.9% |
| STATE STREET CORP | 7.1M | $22M | 5.49% | +39.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.7M | $17M | 4.35% | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.4M | $17M | 4.14% | new |
| MARSHALL WACE, LLP | 4.0M | $12M | 3.09% | +335.4% |
| MILLENNIUM MANAGEMENT LLC | 3.3M | $10M | 2.50% | +1471.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 3.1M | $10M | 2.39% | +35.5% |
| Alyeska Investment Group, L.P. | 2.6M | $8M | 2.03% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$0.18 | — | — | — |
| 2025-12-31 | 2026-03-05 | — | — | $26,000 | +420.0% |
| 2025-09-30 | 2025-11-06 | −$0.21 | — | $5,000 | +0.0% |
| 2025-06-30 | 2025-08-12 | −$0.27 | — | $5,000 | +0.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
